Abstract
Rare diseases, which are often complex genetic conditions that are either life threatening or chronic and debilitating, are rightly seen as a growing public health priority in the European Union. The European Union considers a disease to be “rare” if it does not affect more than “1 per 2,000 persons”. It is estimated, that there are between six to seven thousand identified rare diseases to date, with approximately five new diseases described every week in the medical literature [1]. Both the European Commission and several EU Council Presidencies have identified Rare Diseases as a key area in healthcare policy. The recently published European Commission proposals outline the necessary steps for an efficient policy addressing the issue of rare diseases in Europe. http://ec.europa.eu/health/ph threats/non com/ rare 10 en.htm. It is within this context that increased attention is being given by the EU to rare plasma related disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
